nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0268	0.0268	CcSEcCtD
Loxapine—Seborrhoeic dermatitis—Fludarabine—lymphatic system cancer	0.0223	0.0223	CcSEcCtD
Loxapine—Ileus paralytic—Vincristine—lymphatic system cancer	0.0215	0.0215	CcSEcCtD
Loxapine—Numbness—Fludarabine—lymphatic system cancer	0.0184	0.0184	CcSEcCtD
Loxapine—Sensory loss—Fludarabine—lymphatic system cancer	0.0176	0.0176	CcSEcCtD
Loxapine—Jaundice—Mechlorethamine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Loxapine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Loxapine—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Loxapine—Numbness—Vincristine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Loxapine—Wheezing—Bleomycin—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Loxapine—Sensory loss—Vincristine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Loxapine—Bronchospasm—Teniposide—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Loxapine—Alopecia—Mechlorethamine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Loxapine—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Loxapine—Gait disturbance—Carmustine—lymphatic system cancer	0.00999	0.00999	CcSEcCtD
Loxapine—Dysphagia—Fludarabine—lymphatic system cancer	0.00956	0.00956	CcSEcCtD
Loxapine—Gait disturbance—Vincristine—lymphatic system cancer	0.00954	0.00954	CcSEcCtD
Loxapine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Loxapine—Gynaecomastia—Carmustine—lymphatic system cancer	0.00872	0.00872	CcSEcCtD
Loxapine—Renal failure—Fludarabine—lymphatic system cancer	0.00838	0.00838	CcSEcCtD
Loxapine—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00827	0.00827	CcSEcCtD
Loxapine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00821	0.00821	CcSEcCtD
Loxapine—Alopecia—Teniposide—lymphatic system cancer	0.00769	0.00769	CcSEcCtD
Loxapine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Loxapine—Agitation—Teniposide—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Loxapine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Loxapine—Leukopenia—Teniposide—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Loxapine—Alopecia—Fludarabine—lymphatic system cancer	0.00676	0.00676	CcSEcCtD
Loxapine—Hypertension—Teniposide—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Loxapine—Chest pain—Teniposide—lymphatic system cancer	0.00645	0.00645	CcSEcCtD
Loxapine—Urinary retention—Vincristine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Loxapine—Weight decreased—Bleomycin—lymphatic system cancer	0.00634	0.00634	CcSEcCtD
Loxapine—Confusional state—Teniposide—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Loxapine—Oedema—Teniposide—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Loxapine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Loxapine—Agitation—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Loxapine—Dysphagia—Carmustine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Loxapine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Loxapine—Tachycardia—Teniposide—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Loxapine—Leukopenia—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Loxapine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00593	0.00593	CcSEcCtD
Loxapine—Cough—Fludarabine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Loxapine—Hypotension—Teniposide—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Loxapine—Convulsion—Fludarabine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Loxapine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Loxapine—Dyspnoea—Teniposide—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Loxapine—Confusional state—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Loxapine—Oedema—Fludarabine—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Loxapine—Renal failure—Carmustine—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Loxapine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Loxapine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Loxapine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Loxapine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Loxapine—Rash—Mechlorethamine—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Loxapine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Loxapine—Weight decreased—Vincristine—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Loxapine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Loxapine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Loxapine—Feeling abnormal—Teniposide—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Loxapine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Loxapine—Renal failure—Mitoxantrone—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Loxapine—Nausea—Mechlorethamine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Loxapine—Alopecia—Bleomycin—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Loxapine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Loxapine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Loxapine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Loxapine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Loxapine—Dysarthria—Methotrexate—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Loxapine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Loxapine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Loxapine—Fatigue—Fludarabine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Loxapine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Loxapine—Constipation—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Loxapine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Loxapine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Loxapine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Loxapine—Asthenia—Teniposide—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Loxapine—Pruritus—Teniposide—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Loxapine—Leukopenia—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Loxapine—Alopecia—Carmustine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Loxapine—Cough—Bleomycin—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Loxapine—Angiopathy—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Loxapine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Loxapine—Chest pain—Bleomycin—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Loxapine—Alopecia—Vincristine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Loxapine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Loxapine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Loxapine—Confusional state—Bleomycin—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Loxapine—Vision blurred—Carmustine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Loxapine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Loxapine—Tremor—Carmustine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Loxapine—Oedema—Bleomycin—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Loxapine—Vomiting—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Loxapine—Agitation—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Loxapine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Loxapine—Asthenia—Fludarabine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Loxapine—Rash—Teniposide—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Loxapine—Dermatitis—Teniposide—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Loxapine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Loxapine—Headache—Teniposide—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Loxapine—Pruritus—Fludarabine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Loxapine—Leukopenia—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Loxapine—Agitation—Vincristine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Loxapine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Loxapine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Loxapine—Hypotension—Bleomycin—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Loxapine—Convulsion—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Loxapine—Hypertension—Carmustine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Loxapine—Nausea—Teniposide—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Loxapine—Leukopenia—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Loxapine—Chest pain—Carmustine—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Loxapine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Loxapine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Loxapine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Loxapine—Convulsion—Vincristine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Loxapine—Hypertension—Vincristine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Loxapine—Confusional state—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Loxapine—Oedema—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Loxapine—Cough—Mitoxantrone—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Loxapine—Vomiting—Fludarabine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Loxapine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Loxapine—Rash—Fludarabine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Loxapine—Dermatitis—Fludarabine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Loxapine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Loxapine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Loxapine—Headache—Fludarabine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Loxapine—Tachycardia—Carmustine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Loxapine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Loxapine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Loxapine—Oedema—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Loxapine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Loxapine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Loxapine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Loxapine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Loxapine—Hypotension—Carmustine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Loxapine—Oedema—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Loxapine—Nausea—Fludarabine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Loxapine—Shock—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Loxapine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Loxapine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Loxapine—Insomnia—Carmustine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Loxapine—Paraesthesia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Loxapine—Hypotension—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Loxapine—Dyspnoea—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Loxapine—Somnolence—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Loxapine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Loxapine—Insomnia—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Loxapine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Loxapine—Paraesthesia—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Loxapine—Constipation—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Loxapine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Loxapine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Loxapine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Loxapine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Loxapine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Loxapine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Loxapine—Fatigue—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Loxapine—Asthenia—Bleomycin—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Loxapine—Constipation—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Loxapine—Pruritus—Bleomycin—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Loxapine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Loxapine—Constipation—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Loxapine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Loxapine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Loxapine—Vomiting—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Loxapine—Rash—Bleomycin—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Loxapine—Dermatitis—Bleomycin—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Loxapine—Asthenia—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Loxapine—Renal failure—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Loxapine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Loxapine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Loxapine—Asthenia—Vincristine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Loxapine—Nausea—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Loxapine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Loxapine—Dizziness—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Loxapine—Vomiting—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Loxapine—Dizziness—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Loxapine—Rash—Carmustine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Loxapine—Dermatitis—Carmustine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Loxapine—Headache—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Loxapine—Vomiting—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Loxapine—Rash—Vincristine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Loxapine—Dermatitis—Vincristine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Loxapine—Headache—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Loxapine—Nausea—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Loxapine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Loxapine—Rash—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Loxapine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Loxapine—Headache—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Loxapine—Alopecia—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Loxapine—Nausea—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Loxapine—Nausea—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Loxapine—Cough—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Loxapine—Convulsion—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Loxapine—Chest pain—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Loxapine—Confusional state—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Loxapine—Hypotension—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Loxapine—Insomnia—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Loxapine—Somnolence—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Loxapine—Fatigue—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Loxapine—Asthenia—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Loxapine—Pruritus—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Loxapine—Dizziness—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Loxapine—Vomiting—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Loxapine—Rash—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Loxapine—Headache—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Loxapine—Nausea—Methotrexate—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
